

## Frequently asked Questions & Answers about *Ajovy*® (fremanezumab)

From 1<sup>st</sup> August 2021 ***Ajovy*® (fremanezumab)** is the second first PBS-listed CGRP treatment for chronic migraine. The PBS listing is similar criteria to the previous listing for Emgality in this same class of treatment.

### ***Who can access this treatment?***

People with chronic migraine meeting the eligibility criteria set by PBS will be able to access *Ajovy*®. This includes:

- ✓ 15 or more headache days per month, with at least 8 days of migraine, over a period of at least 6 months
- ✓ Inadequate response, intolerance or a contraindication to at least three prophylactic migraine medications (preventers)

### ***How much will *Ajovy*® cost?***

*Ajovy*® will be available for the standard PBS co-payment price, which is usually \$41.30 or \$6.60 for concession holders

### ***Where can I get *Ajovy*®?***

*Ajovy*® will be available at any pharmacy but will need to be ordered to the pharmacy a day or two prior to supply.

### ***Who can prescribe *Ajovy*®?***

Treatment with *Ajovy*® must be initiated by a neurologist who will need an Authority streamline code to write the prescription (12064 for initial script of 3 months supply; one prefilled syringe with 2 repeats).

### ***Can I access *Ajovy*® on the PBS if I am also having treatment with *Botox*® through the PBS?***

No. Under the current PBS listing, *Ajovy*® cannot be prescribed to people who are also receiving botulinum toxin (*Botox*®) at a subsidised cost through the PBS.

### ***Can I access *Ajovy*® for episodic migraine?***

Access to *Ajovy*® for people who do not meet the PBS reimbursement criteria for chronic migraine will continue to have a special private pay price through partnering pharmacies via the Momentum Program. Please contact your Teva representative for details.